Tuesday, 20 Nov 2018

You are here

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice. (Citation source https://buff.ly/2te3GpP)

Hyperactivation (serine/threonine kinase that phosphorylates the insulin receptor substrate-1) of S6K1 due to overnutrition leads to hyperglycemia and type 2 diabetes in mice.

Investigators have shown that A77 1726 (active metabolite of leflunomide) is an inhibitor of S6K1 and tested if leflunomide can control hyperglycemia and sensitize the insulin receptor.

They tested leflunomide on ob/ob and high-fat diet (HFD)-induced diabetes mice and found leflunomide normalized blood glucose levels and overcame insulin resistance ob/ob and HFD-fed mice but had no effect on mice fed a normal chow diet (NCD).

They believe  that leflunomide sensitizes the insulin receptor by inhibiting S6K1 activity and could be potentially useful for treating patients with both RA and diabetes.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CIRT Trial - Methotrexate Fails at Cardiovascular Prevention

Methotrexate has been shown to reduce cardiovascular (CV) deaths in rheumatoid arthritis (RA) patients. Given that inflammation underlies the pathogenesis of atherothrombosis, Dr. Paul Ridker and colleagues studied the value of low dose methotrexate (MTX) in preventing cardiovascular events.

ACR 2018 Podcast - Day 3

Audio Highlights and Interviews from Day 3 at the ACR 2018 meeting  LISTEN HERE

ACR 2018 - Day 3 Report

Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included:

The PEXIVAS Study –  2x2 Trial of Plasma Exchange and Reduced Steroids in ANCA-Associated Vasculitis (AAV) - Abstract #2788

ACR 2018 Podcast - Day 2B

Audio Highlights and Interviews from Day 2 at the ACR 2018 meeting - LISTEN HERE

ACR 2018 Podcast - Day 1B

Audio Highlights and Interviews from Day 1 at the ACR 2018 meeting - LISTEN HERE